Fluorexetamine (FXE/3F-2-oxo-PCE): Complete Toxicology, Isomer Confusion & Safety Monograph

Fluorexetamine (FXE/3F-2-oxo-PCE): Complete Toxicology, Isomer Confusion & Safety Monograph

Emergency dissociative toxicity: Severe unresponsiveness, seizure, abnormal breathing, persistent vomiting with reduced consciousness, dangerous agitation/confusion, collapse, or serious injury after an unknown dissociative requires urgent medical care.

Quick answer

Fluorexetamine (FXE) is a fluorinated ketamine/O-PCE-related arylcyclohexylamine dissociative, commonly described chemically as 3F-2-oxo-PCE.

The most important fact is not a potency claim.

It is an identity problem:

FXE and 2F-2-oxo-PCE (CanKet) are positional isomers.

Some analytical methods historically reported an “FXE-like” result without actually determining whether the fluorine was in the 2- or 3-position.

Later work showed that much North American material thought to be FXE was actually 2F-2-oxo-PCE.

Therefore old “FXE case” claims require method-specific scrutiny.

Identity

History and emergence

Recreational FXE use was reported by the late 2010s.

CFSRE's first U.S. report came from a toxicology specimen received in October 2022.

The original report contained a crucial analytical warning:

The fluorine position was not confirmed during analysis.

That caveat became even more important when later laboratories obtained reference standards for both positional isomers.

Subsequent North American drug-material and casework studies found 2F-2-oxo-PCE/CanKet repeatedly.

This changed how older “FXE” detections should be interpreted.

FXE vs 2F-2-oxo-PCE / CanKet

They have:

• the same molecular formula;
• closely related mass spectra;
• different fluorine positions.

A method that relies only on library mass-spectrum matching may fail to distinguish them.

Why this matters clinically and epidemiologically

If a case is misclassified:

• prevalence numbers become wrong;
• blood concentration references are assigned to the wrong molecule;
• toxicity assumptions can be copied to the wrong isomer.

This is not academic nitpicking.

It directly affects forensic interpretation.

FXE vs 2F-DCK

FXE is also not 2F-DCK.

Both are fluorinated ketamine analogues, but:

• 2F-DCK has a methylamino substituent;
• FXE has an ethylamino substituent;
• metabolic profiles can overlap enough to cause analytical confusion in routine workflows.

Hong Kong investigators reported that FXE did not cross-react with a bedside ketamine immunoassay and shared metabolites with 2F-DCK.

Pharmacology

Direct experimental FXE pharmacology remains limited.

Based on its arylcyclohexylamine structure and clinical phenotype, it is expected to act as an NMDA receptor antagonist.

That is a strong class inference, not a completed human receptor/PK program.

No controlled study establishes:

• receptor potency versus ketamine;
• human dose equivalence;
• therapeutic index.

Human clinical surveillance

Hong Kong

A 2024 Hong Kong Medical Journal report described increasing FXE detections beginning in mid-2023.

The laboratory had identified FXE in urine from 14 patients.

The authors reported that:

• clinical toxicity appeared similar to ketamine/2F-DCK;
• co-ingestion with other recreational drugs was common;
• routine ketamine immunoassay did not detect FXE;
• shared metabolites could produce confusion with 2F-DCK.

This is useful real-world evidence, but not a controlled single-drug clinical series.

French addictovigilance

A 2026 French national study included FXE among five ketamine analogues.

Across the entire 56-case analogue cohort:

• neurological/psychiatric effects predominated;
• 61% were classified as serious;
• 11% were deaths.

Most cases involved 2F-DCK and O-PCE.

Those percentages therefore must not be reported as FXE-specific risk rates.

FXE was part of the monitored market, not necessarily the primary drug in each event.

DEA TOX fatal detection

DEA TOX reported one Q4-2024 case in Maryland in which fluorexetamine was detected in whole blood at 151 ng/mL and the case was fatal.

This is a safety signal.

It does not prove:

• FXE alone caused death;
• 151 ng/mL is a lethal threshold;
• every lab would resolve the isomer identically.

Case-level co-drug and causation details are necessary before stronger conclusions.

Acute toxicity

Based on human surveillance and ketamine-analogue evidence, potential effects include:

• dissociation;
• impaired consciousness;
• confusion;
• agitation;
• psychomotor impairment;
• hypertension/tachycardia;
• nausea/vomiting;
• loss of coordination;
• accident/injury risk.

Severe outcomes can involve:

• deep unconsciousness;
• aspiration;
• traumatic injury;
• polysubstance respiratory compromise.

Interactions

No controlled FXE interaction trials exist.

Highest-concern contexts include:

• alcohol/benzodiazepines → deeper unconsciousness/aspiration;
• opioids → respiratory-depression risk from opioid component;
• other dissociatives → unpredictable depth and duration;
• stimulants → cardiovascular/behavioral stress.

French surveillance also documented substituted/adulterated exposures, meaning the user may not know FXE is present.

Product substitution and unexpected exposure

The French study identified a user profile involving unintentional exposure to substituted substances, including products sold as:

• synthetic cathinones;
• cocaine;
• ketamine.

That general ketamine-analogue pattern is particularly relevant to FXE/CanKet because these molecules circulate in dynamic NPS markets.

Metabolism

FXE-specific human metabolism remains poorly characterized.

Hong Kong investigators noted metabolite overlap with 2F-DCK, which can complicate identification.

It is therefore inappropriate to publish a complete metabolite map borrowed from 2F-DCK or O-PCE.

Pharmacokinetics

No controlled human FXE study establishes:

• bioavailability;
• time to peak;
• half-life;
• clearance;
• accumulation;
• exposure-response.

Community duration estimates are not measured PK.

Drug testing

Bedside ketamine immunoassay

The Hong Kong report specifically noted that FXE does not cross-react with their bedside ketamine immunoassay.

Therefore a negative ketamine screen does not rule out FXE.

Mass spectrometry

Useful tools include:

• LC-QTOF-MS;
• LC-MS/MS;
• HRMS;
• chromatographic methods capable of resolving positional isomers.

The positional-isomer problem in forensic testing

Early casework often relied on mass spectral matching.

But FXE and 2F-2-oxo-PCE can be indistinguishable under some methods.

Later standard-addition and chromatographic work showed the importance of reference standards and retention-time separation.

A high-quality report should state whether the method could actually resolve the isomers.

Tolerance

Repeated NMDA-antagonist use can produce tolerance.

There are no controlled FXE-specific human tolerance studies.

Tolerance to subjective dissociation does not prove protection from:

• accidents;
• impaired driving;
• unconsciousness;
• urinary/cognitive toxicity;
• mixed-drug risk.

Dependence and substance use disorder

French ketamine-analogue surveillance included regular users and substance-use-disorder concerns.

However, it did not establish an FXE-specific incidence.

The responsible conclusion is:

Repeated FXE/ketamine-analogue use can plausibly become problematic, but direct FXE dependence epidemiology is absent.

Withdrawal

No validated FXE withdrawal syndrome or timeline exists.

Frequent dissociative users may experience:

• craving;
• low mood;
• irritability;
• anxiety;
• sleep disturbance;
• difficulty stopping.

These should not be presented as an FXE-specific clock.

Treatment and support

No medication is approved specifically for FXE use disorder.

Acute severe intoxication is managed supportively according to:

• consciousness/airway;
• cardiovascular state;
• co-drugs;
• agitation;
• trauma.

For repeated problematic use, substance-use treatment can address behavior and co-occurring conditions.

U.S. resources include FindTreatment.gov and SAMHSA 1-800-662-HELP (4357).

Bladder and urinary risk

Ketamine can cause severe urinary-tract injury with repeated heavy exposure.

Direct FXE cystitis incidence is not established.

Because FXE is a ketamine-related arylcyclohexylamine, urinary toxicity is a class-level concern, not a quantified FXE-specific fact.

Persistent urinary pain, urgency, frequency or blood in urine warrants medical evaluation.

Cognitive and psychiatric risk

Long-term controlled FXE studies are absent.

Potential class-level concerns include:

• cognitive impairment;
• dissociation-related functional impairment;
• anxiety/psychosis in vulnerable people;
• accidents.

Forensic interpretation

Detection vs cause of death

The DEA TOX fatal detection proves exposure.

It does not prove sole causation.

Isomer identity must be demonstrated

Before calling a case “FXE,” laboratories should document that their method separates:

• 3F-2-oxo-PCE (FXE);
• 2F-2-oxo-PCE (CanKet).

No universal fatal concentration

There is no validated FXE lethal blood level.

Special populations

No adequate FXE-specific data exist for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular disease;
• urinary disease;
• severe psychiatric illness;
• liver/kidney impairment.

Legal status — dated October 2, 2026

CFSRE's current monograph describes fluorexetamine as not explicitly scheduled in the United States.

This review did not identify a later primary federal scheduling action specifically naming FXE.

Do not confuse FXE with:

• 2F-DCK, which has a separate federal control history;
• 2F-2-oxo-PCE/CanKet, a positional isomer with separate surveillance and regulatory issues.

Federal analogue law and state laws may still apply depending on facts and jurisdiction.

Myths and misconceptions

“FXE and CanKet are the same drug.”
No. They are positional isomers.

“Every older lab report calling something FXE definitely proved 3F-FXE.”
False. Some methods could not resolve fluorine position.

“A negative ketamine screen rules out FXE.”
False.

“The DEA fatal case proves 151 ng/mL is lethal.”
False. Detection in one fatal case is not a threshold.

“FXE has the same bladder risk as ketamine.”
Not quantified. It is a class concern, not a proven incidence.

Evidence ledger

Related evidence

• 2F-2oxo-PCE / CanKet
• 2F-DCK
• DCK
• O-PCE
• DMXE
• 3-MeO-PCE
• RC dissociatives evidence hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

FXE's most important modern lesson is analytical humility.

The drug is real and has appeared in human casework, including serious and fatal surveillance contexts.

But the positional isomer 2F-2-oxo-PCE/CanKet has repeatedly been mistaken for or grouped with FXE.

So the scientifically useful question is not merely “was FXE detected?”

It is:

Did the analytical method actually prove which fluoro-2-oxo-PCE isomer was present?

That distinction protects both clinical interpretation and the accuracy of the site's evidence database.